Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

• Incidence of Adverse Events [ Time Frame: during open-label drug exposure up to database cutoff (max 40 months) ] [ Designated as safety issue: Yes ]
  Adverse events were the primary means to assess safety.
  
  

• Time to Discontinuation [ Time Frame: during open-label extension up to date of discontinuation; subjects who continue in the study are censored at database cutoff (max 40 months) ] [ Designated as safety issue: No ]
  Time to discontinuation in number of days since first dose in open-label extension until subject discontinues
  
  
• The number and percent of subjects exposed to study drug [ Time Frame: for at least 3, 6, 12, 18, 24 and 32 months ] [ Designated as safety issue: No ]
  The number and percent of subjects exposed to study drug
  
  
• Listing of abnormal liver function test results and liver adverse events [ Time Frame: during open-label drug exposure up to database cutoff (max 40 months) ] [ Designated as safety issue: Yes ]
  Abnormal lab results if reported as adverse events or values of alkaline phosphatase, alanine transaminase, aspartate transaminase [>3, >5, >10xupper limit of normal (ULN)] or total bilirubin (>1.5, >2, >4xULN); treatment emergent adverse events related to liver function test abnormalities
  
  
• Observed values and change from baseline summaries for American Urological Association symptom index scores, Post-Void Residual bladder ultrasound, Vital Signs and Weight [ Time Frame: baseline (parent study) and at 1, 3, 12, 24 and 36 months ] [ Designated as safety issue: Yes ]
  Univariate statistics summarizing the observed values and change from baseline, using parent study baseline value
  
  
• Percent change from baseline in seizure frequency [ Time Frame: entire open-label extension period up to database cutoff (max 40 months) ] [ Designated as safety issue: No ]
  Percent change from baseline in 28-day total partial seizure frequency, using parent study baseline value.
  
  
• Number and percent of responders [ Time Frame: entire open-label extension period up to database cutoff (max 40 months) ] [ Designated as safety issue: No ]
  Number and percent of responders (defined as subjects with >=50% reduction from baseline in 28-day total partial seizure frequency) using parent study baseline value
  
  
• Number and percent of seizure free subjects [ Time Frame: during open-label drug exposure up to database cutoff (max 40 months) ] [ Designated as safety issue: No ]
  Percent of subjects seizure free for any 6 continuous months or longer for subjects treated for at least 6, 12 and 24 months; percent of seizure free subjects for any 12 continuous months or longer for subjects treated for at least 12 and 24 months
  
  
• Proportion of subjects retained in the study [ Time Frame: at 3, 6, 12, 24 and 32 months after exposure to first dose in open-label extension study. ] [ Designated as safety issue: No ]
  Length of time subjects retained in OLE as summarized by proportion of subjects remaining in both studies at given timepoints.
  
  
• Mean of average dose [ Time Frame: entire open-label drug extension period up to database cutoff (max 40 months) ] [ Designated as safety issue: No ]
  Mean average dose for all subjects combined and by modal dose category [the range of doses (<=750 mg/day, >750 to 1050 mg/day, >1050 mg/day) taken most frequently].
  
  

Data from the October 2009 data-cut of ongoing Studies VRX-RET-E22-303 (Study 303) and VRX-RET-E22-304 (Study 304) will be pooled, summarized, and published with the goal of providing updated long-term safety and efficacy information for subjects and prescribers following the recent positive CHMP opinion for retigabine for adjunctive use in patients with partial seizures. Studies 303 and 304 are the open-label extensions of two Phase 3 studies (VRX-RET-E22-301 and VRX-RET-E22-302), respectively. Studies 301 and 302 were randomized, double-blind, placebo-controlled, parallel-group, multicenter studies of 600 mg and 900 mg per day (Study 302) and 1200 mg per day (Study 301). All subjects who wished to enter the OLE studies and, in the opinion of the investigator, were expected to benefit from participation in the OLEs, entered a 6-week (Study 301) or 4-week (Study 302) transition phase in which their dose of retigabine was titrated to or maintained at 400 mg TID (Study 301) or 300 mg TID (Study 302). Upon completion of the Transition phase, subjects enrolled into the extension studies. Once enrolled in the OLE, doses could be adjusted within the range of 600 mg to 1200 mg per day. Treatment in Studies 303 and 304 is planned to continue until regulatory approval and commercialization of retigabine or until the program is discontinued.